Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma
Status:
Unknown status
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Treatment of locally advanced and metastatic squamous cell carcinoma of the lung involves the
use of chemotherapy as the therapeutic mainstay. Platinum-etoposide regimens (such as
cisplatin-etoposide) are the most commonly used chemotherapeutic regimen, which is delivered
intravenously in the standard three-weekly intervals.
Recent interest in oral metronomic chemotherapy has arisen, especially due to its beneficial
effects in delaying disease progression among heavily pre-treated patients with various
malignancies.
This study attempts to combine the use of metronomic chemotherapy concurrently during
standard intravenous chemotherapy.